 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Ahn Jae-yong, CEO of SK Bioscience, received the highest salary among incumbent executives in the pharmaceutical and bio industries in the first half of this year. Ahn also became the industry's 'annual salary king' last year.
According to the semiannual report of the domestic pharmaceutical and bio industry on the 15th, CEO Ahn received 3.65 billion won in compensation in the first half of this year, the largest amount in the industry. Ahn received 350 million won in salary and 3.3 billion won in bonuses. Bonuses include 300 million won in management performance for last year's performance and 3 billion won in special compensation for the past three years of management performance.
Ahn received about 7.2 billion won in compensation last year, the largest amount in the industry.
Kim Hoon, CEO of Global R&BD of the same company, also received a total of 3.6 billion won in compensation in the first half of this year. The salary is 300 million won and the bier is 3.3 billion won, which is similar to Ahn.
In a report, the company said it paid management performance benefits by comprehensively evaluating quantitative indicators consisting of sales, operating profit, pre-tax profit and net profit, and non-metering indicators consisting of leadership, expertise and other company contributions. The size of the incentive is determined within 200% of the annual salary.
Meanwhile, the CEO of Samsung BioLogics, who achieved the best performance in the first half of this year, received a salary of 1.038 billion won. It is about 850 million won in salary, 80 million won in bonuses, and about 100 million won in welfare benefits. I got paid around 1 billion won.
In addition, Lee Jang-han, chairman of Chong Kun Dang Holdings, paid about 890 million won in the first half of the year, Handok Chairman Kim Young-jin 640 million won, and Samjin Pharmaceutical Chairman Choi Seung-joo and Cho Ui-hwan 580 million won, respectively.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
